Surrozen Inc. (SRZN)
SRZN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$23.51
-5.05% on the day
Market cap
$276.3M
Micro cap
Revenue · 2025
$3.5M
-67.4% on 2024
Net income · 2025
-$242.0M
-6960.8% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SRZN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001824893 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.5M |
| Net income | -$242.0M |
| Operating income | -$42.1M |
| Net margin | -6960.8% |
| Operating margin | -1210.6% |
| Revenue growth | -67.4% |
| Cash | $89.2M |
| Total assets | $98.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 79.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-30 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-02 |
| Latest proxy | DEFA14A | 2026-04-01 |
Source: SEC EDGAR submissions feed, 492 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CABA | Cabaletta Bio Inc. | $1.69 | -5.59% | $286.5M |
| XFOR | X4 Pharmaceuticals Inc. | $2.60 | -7.80% | $257.8M |
| PALI | Palisade Bio Inc. | $1.47 | -7.86% | $255.3M |
| OCGN | Ocugen Inc. | $0.8854 | -6.52% | $300.2M |
| IRLA | IRulya Therapeutics Inc. | $27.87 | -13.98% | $302.2M |
| IPSC | Century Therapeutics Inc. | $1.38 | -4.17% | $249.9M |
| ARTV | Artiva Biotherapeutics Inc. | $6.29 | -7.09% | $307.5M |
| IKT | Inhibikase Therapeutics Inc. | $1.76 | -4.61% | $245.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier